Notes on AI, drug discovery, and building platforms in biomedicine. Short posts. No listicles. Occasional diagrams.
The bottleneck in AI for drug development is no longer the model. It is the shortage of people who can hold the clinical, regulatory and computational picture in their head at the same time — and frame the question before anyone writes a line of code.
